|
|
 |
|
Viewing report
|
|
|
|
Pipeline and Commercial Insight: Alzheimers Disease - Scenario Forecasts Reveal Vast Market Potential
Datamonitor, March 2008, Pages: 222
With the AD market entering a pivotal phase, We have conducted several scenario forecasts in order to explore the possible market outlook over the next 10 years. Several pioneering Phase III disease slowing therapies offer blockbuster potential. However, should these drugs fail Phase III trials, generic competition of current therapies will see the market value decline.
Scope
- Overview of key marketed brands and late-stage pipeline drugs.
- Indication-specific sales volume and value forecasts to 2017 under four different scenarios.
- Identification of future market events that are expected to affect AD drug revenues.
- Analysis of patient potential, unmet needs and clinical trial design in AD.
Highlights of this title
The base scenario reveals three blockbuster potentially disease slowing drugs in the current late-stage pipeline. Wyeth/Elans bapineuzumab has potential to generate multi-billion dollar revenues, and become one of the most lucrative drugs in medicine.
The entry of potentially disease slowing therapies will not have a significant negative impact on the sales of branded current treatments. Along with the likely use of combined disease slowing and symptomatic treatments, slowing disease progression might actually increase the therapeutic window for symptomatic drugs.
Scenario forecasts reveal a future upper limit market value of $12.7 billion to a lower limit value of $1.9 billion across the seven major markets in 2017. The affect on forecast sales revenues of different US AD prevalence rates and the success or failure of clinical programs on each key pipeline drug is explored.
Key reasons to purchase this title
- Appreciate the lucrative potential of disease slowing AD therapies, and the impact of this class on the currently marketed symptomatic drugs.
- Assess region- (US, Japan and 5EU) and scenario-specific sales forecasts of key late-stage pipeline drugs and marketed brands.
- Understand unmet needs and opportunities in the AD market based on key opinion leader comments.
Customers who bought this item also bought
Prospects for the Phase III Bapineuzumab Trial
Forecast Insight: Parkinson's Disease - Market Upgrade following Evidence of Disease Slowing with Azilect
Alzheimers and Parkinsons Disease - Global Strategic Business Report
Alzheimers Disease - Beta Treatments On The Horizon
Mild Cognitive Impairment - Unlocking the Potential of Prodromal Alzheimer's Disease and Beyond
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntingtons Disease
Disease Specific Markers Clinical Trial Analysis
Forecast Insight: Dyslipidemia - Genericization and Negative Trial Data Drive Market Shrinking
Trial TRAX - Alzheimer's Disease - Clinical Trial Monitoring Brief
Antibody drug conjugates for cancer treatment: Clinical Trial Pipeline
Drug Eluting Stent (DES) Clinical Trial Analysis
Bapineuzumab Phase 2 Clinical Trial Results Call - Wyeth,Elan Corp. Plc, - Earnings Transcript
|
|
|
|
